Literature DB >> 11806151

Combination therapy including pentoxifylline for entero-Behçet's disease.

T Hisamatsu1, H Kishikawa, H Fukuya, K Matsuoka, Y Mizuno, J Nishida.   

Abstract

Behçet's disease is a chronic relapsing vasculitis characterized by recurrent aphthous oral and genital ulcerations with uveitis. Multiple organs can be involved. Entero-Behçet's disease is often uncontrollable, relapsing, and can cause acute intestinal bleeding or perforation. We utilized a combination therapy including 600 mg of pentoxifylline per day, in two doses, to treat three female patients and observed the subsequent changes in clinical symptoms, serum C reactive protein levels, and endoscopic findings. In all three patients, clinical symptoms as well as serum C reactive protein levels improved immediately. Endoscopically, lower intestinal lesions were significantly reduced or healed in all of them. Combination therapy including pentoxifylline appears to be clinically effective in the patients with entero-Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806151     DOI: 10.2209/tdcpublication.42.169

Source DB:  PubMed          Journal:  Bull Tokyo Dent Coll        ISSN: 0040-8891


  3 in total

1.  A rare manifestation of Behçet's syndrome: immunological correlates and successful treatment of an esophageal ulcer.

Authors:  Heiner Wedemeyer; Jens G Kuipers; Konrad Streetz; Michael Mengel; Ingolf Schedel; Nikolina Kezmic; Peter Meier; Henning Zeidler; Michael P Manns; Siegfried Wagner
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

2.  Successful treatment with infliximab for refractory para-ileostomal ulceration in a patient with Behҫet's disease.

Authors:  Mitsuaki Ishioka; Kengo Onochi; Yusato Suzuki; Masayuki Sawaguchi; Natsumi Hatakeyama; Shigeto Koizumi; Tamotsu Matsuhashi; Mario Jin; Hirohide Ohnishi
Journal:  Clin J Gastroenterol       Date:  2015-06-09

3.  Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report.

Authors:  Yue Li; Zelong Han; Xianfei Wang; Zhihui Mo; Wei Zhang; Aimin Li; Side Liu
Journal:  BMC Gastroenterol       Date:  2013-12-09       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.